Generative AI for regulated marketing, with the evidence attached.
Pharma and medtech marketing teams are under pressure to produce more localised, channel-specific content, while every claim still has to survive medical, legal and regulatory review. We help life sciences companies and the platforms that serve them build AI content systems that start from approved evidence, and we build them AI-first with senior engineers accountable for accuracy and data handling.
In regulated marketing, the slow part is not writing the content. It is proving every word.
A single detail aid or email can carry a dozen claims, each needing a reference to an approved source, the right safety information, and wording consistent with the product label in that market. Reviewers spend much of their time checking citations and chasing inconsistencies rather than exercising medical or legal judgement.
That is why generic AI writing tools disappoint in life sciences. They make drafting faster, which was never the bottleneck, and they introduce a new risk: fluent, confident text with claims nobody can trace. More drafts entering review with weaker substantiation makes the MLR queue longer, not shorter.
The useful application of AI here works the other way round. It constrains generation to approved claims and evidence, makes substantiation visible to reviewers, and handles the repetitive adaptation work across channels, audiences and markets.
What working on AI for pharma content has taught us
We work with SwishX, an AI content platform for pharma and medtech marketing that produces MLR-ready assets with claims linked to approved evidence. That work has reinforced a few principles we would apply to any life sciences content system.
First, the claims library is the product. If approved claims, references and required safety statements are not structured and versioned, no amount of prompt engineering will make generated content reliable. Second, traceability has to be visible in the asset itself, so a reviewer can click from a sentence to the supporting page of the source. Third, the system must respect the difference between audiences: what is appropriate for a healthcare professional differs from patient-facing material, and both vary by market.
Finally, AI supports the review process; it does not replace it. Human reviewers remain accountable for approval, and the technology should make their decisions faster and better documented rather than try to pre-empt them.
An evidence-first generative AI content workflow
Every organisation has its own review process and systems. This is the general shape we recommend, adapted to your SOPs and existing review platform.
Structure the approved claims
Turn approved claims, references, safety statements and brand rules into a versioned, searchable library with market and audience metadata.
Generate only from approved modules
Retrieval-grounded generation assembles and adapts content from the library, flagging any sentence that cannot be linked to a source.
Pre-check before human review
Automated checks for missing references, outdated safety information and prohibited phrasing catch routine issues before reviewers see the draft.
Hand off to your review system
Assets move into the review platform your teams already use, annotated with references, so reviewers keep their familiar process.
Learn from reviewer decisions
Structured feedback on accepted and rejected claims improves the library and the checks over time, within your data governance rules.
Generic AI writing tools versus evidence-grounded content systems
| General-purpose AI writing tools | Evidence-grounded content system | |
|---|---|---|
| Where claims come from | The model and the prompt | An approved, versioned claims library |
| Reference linking | Manual, after the fact | Built in, sentence by sentence |
| Market and audience variants | Rewritten by hand each time | Driven by structured metadata |
| Audit trail for review | Little or none | Sources, versions and decisions recorded |
| Handling of unpublished data | Depends on vendor terms | Controlled within your environment |
| Effect on MLR queue | More drafts, same checking burden | Fewer avoidable review rounds |
Questions to ask any AI content vendor in life sciences
Whether you build, buy or combine both, these questions separate systems designed for regulated content from general tools with a pharma landing page.
Can every generated claim be traced to an approved source?
Ask to see the reference linking in a real asset, not a slide.
What happens when the model cannot find supporting evidence?
The right answer is that it flags or omits the claim, not that it writes around the gap.
Is our data used to train shared models?
Unpublished study data and pipeline plans need contractual and technical protection.
How are label changes and withdrawn claims propagated?
Old assets built on a withdrawn claim should be identifiable quickly.
What does the audit trail look like for an inspection?
Versions, sources, reviewers and approval dates should be retrievable without detective work.
How does it handle possible adverse event mentions?
Any AI that touches inbound HCP or patient messages needs a route into pharmacovigilance processes.
Questions we often hear
Can generative AI be used for pharmaceutical marketing content?
Yes, when it is grounded in approved claims and evidence and the output still goes through your medical, legal and regulatory review. The strongest use cases are adapting approved content across channels, formats and markets, and pre-checking references and safety information. Free-form generation of new promotional claims is where the risk sits.
Does AI replace MLR review?
No. Accountability for approving promotional and medical content stays with qualified human reviewers. Well-designed AI shortens the process by removing avoidable errors before review and making substantiation easy to verify, so reviewers spend their time on judgement rather than citation checking.
How do you stop AI from inventing claims or references?
By limiting generation to retrieved, approved material, requiring every claim to link to a specific source, and flagging or blocking sentences that cannot be linked. Automated checks and human review then act as further layers. No model is perfectly reliable, so the design assumes errors will happen and makes them visible.
Is this relevant for medtech as well as pharma?
Yes. Medtech marketing has its own constraints, such as consistency with indications and instructions for use, and different device regulations by market, but the underlying need for traceable claims and controlled adaptation is the same. The claims library and checks are configured to each regulatory context.
Will an AI content system work with our existing review platform?
It should. Many life sciences companies run content through an established review platform, and a sensible AI workflow feeds into that process rather than replacing it. The integration approach depends on your platform, configuration and SOPs, which is one of the first things we would assess.
Related reading and tools
Tell us how content moves through review today.
Share where your marketing or medical content slows down, what tools you use and what you have tried with AI. We will reply within 24 hours with an honest view of what is realistic.
Working with companies globally · Response within 24 hours